Herpes Cure Advocacy is pleased to report that with the passing of FY 2022 budget that the Dept. of Health and Human Services National Strategy and Strategic Plan for the treatment and prevention of Herpes Simplex Virus has a budget of $250,000.
This small investment in strategic planning is an important step forward in the field that has been stagnant for many years.
Please view the budget report here, page 110, which reads: “In addition, the agreement includes $250,000 for OASH to develop a national strategic plan or amend the STIs National Strategic Plan for the treatment and prevention of HSV types 1 and 2.”
Herpes Cure Advocacy will continue to advocate for federal investment in the treatment and prevention of herpes simplex, for funding for the implementation of this OASH FY 2022 plan, clinical research for treatment, impacts and risk of neurological complications, and a working group led by the CDC to develop a serology test to accurately diagnose asymptomatic infection.
Amazing! Super proud of HCA (: